Genetic Basis of Odor Discrimination
This study has been completed.
Information provided by (Responsible Party):
First received: December 23, 2009
Last updated: September 5, 2012
Last verified: September 2012
Prior to the main study we will perform a pilot study on 60 subjects. The purpose of the pilot study is to identify the range of odor concentrations that will be used in the main study and to optimize the tasks performed in the main study.
||Time Perspective: Prospective
||Genetic Basis of Odor Discrimination
Primary Outcome Measures:
- Percentage of correct responses when discriminating between (-)-carvone and (+)-carvone, isovaleric acid and isobutyric acid, androstenone and androstadienone DNA sequence of ORs sensitive to these odors [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Secondary Outcome Measures:
- concentration at which odors need to be added to allow for discrimination; thresholds to all six odors; verbal descriptors assigned to all six odors [ Time Frame: 3 years ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2012 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years to 50 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Age 18-50
- Current non-smokers
- Current smokers
- Allergy to fragrances or smells of any kind
- Active head cold, upper respiratory infection, or seasonal nasal allergies
- History of nasal health problems, including endoscopic nasal surgery for sinus conditions or polyp removal.
- Pre-existing medical condition that has caused anosmia or near total loss of the sense of smell, such as: head injury, cancer therapy, radiation to head and neck, or alcoholism
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01039935
|The Rockefeller University
|New York, New York, United States, 10065 |
||Leslie Vosshall, PhD
||The Rockefeller University
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 23, 2009
||September 5, 2012
||United States: Institutional Review Board
Keywords provided by Rockefeller University:
ClinicalTrials.gov processed this record on October 19, 2014